Accuray Incorporated's CyberKnife® M6(TM) System Receives Shonin Approval
1310 Chesapeake Terrace
Sunnyvale, CA, 94089
Press release date: March 27, 2014
Latest CyberKnife technology now available in Japan
SUNNYVALE, Calif. - Accuray Incorporated (Nasdaq: ARAY) announced today it received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the CyberKnife® M6™ System to treat radiation therapy patients. The system, which will be marketed in Japan as the "CyberKnife M6 Series," offers the widest range of motion and highest-precision conformal delivery available and enables patients to lie comfortably and breathe freely while receiving precise, high dose radiation therapy in a relatively short number of treatments, reducing side effects and preserving quality of life.
The CyberKnife System enables physicians to precisely maximize dose, minimize side effects and maximize patient comfort. It continues to provide patients in Japan with the latest advances in CyberKnife motion management technology. It automatically adjusts the beam for target movement, enabling reduced margins and minimizing radiation exposure to healthy tissue and critical organs. Patients treated with the CyberKnife System will not experience the discomfort of breath-holding, abdominal compression, breathing apparatus, or metal head-frames typically associated with other radiation therapy devices.
"At Accuray, we understand the priority that our customers place on advanced medical technology and patient comfort," said Juki Hozumi, president and general manager of Japan at Accuray. "We are committed to excellence in service, support and education that will enable our customers to optimize their use of our leading-edge tumor treatments long-term."
"This marks a key milestone in our strategic growth plan for the market in Japan," said Joshua H. Levine, president and chief executive officer of Accuray. "We are very pleased to provide the latest CyberKnife technology to our customers and their patients in Japan. The CyberKnife M6 Series offers advantages of increased clinical flexibility, greatly reduced treatment times and ease of use for clinicians, while providing patients the most precise tumor treatment available."
In July 2010, Accuray was granted Shonin approval of the CyberKnife G4 System for use in Japan in the treatment of tumors in the body, inclusive of the head and neck. In 2012, Accuray received Shonin approval to market the CyberKnife VSI™ System for robotic radiosurgery.
About the CyberKnife System
As the first, and only, robotic full-body radiosurgery system available today, the CyberKnife System is optimized to deliver stereotactic radiosurgery and stereotactic body radiation therapy (SRS/SBRT) non-invasively throughout the body. Its ability to track and automatically correct for tumor motion during treatment enables delivery of high doses of radiation with extreme accuracy, providing customized treatments to meet each patient's needs.
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Contact: Laura Scalley, Schwartz MSL, +1 (781) 684-0770, firstname.lastname@example.org
Web Site: http://www.accuray.com